<DOC>
	<DOCNO>NCT02446691</DOCNO>
	<brief_summary>This Phase IV , Open label , Multicenter study . Subject 's parent and/or legal guardian provide information trial . If interested eligible , ask provide sign informed consent . The initial study visit occur immediately sign inform consent obtain . Approximately 135 subject enrol receive 4 dos intramuscular MenACWY vaccine 2 , 4 , 6 12 month age .</brief_summary>
	<brief_title>Evaluation Antibody Persistence Following 4 MenACWY Vaccinations</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Healthy male female 2 monthold infant ( 55 89 day ) day consent . 2 . Infants whose parent legal guardian voluntary give write informed consent nature study explain accord local regulatory requirement , prior study entry . 3 . Infants whose parent legal guardian comply study procedure include followup 1 . Previously receive meningococcal A , C , W Y vaccine . 2 . Previous confirm suspected disease cause N. meningitidis household contact and/or intimate exposure individual laboratory confirm N. meningitidis infection time since birth . 3 . Progressive , unstable uncontrolled clinical condition . 4 . A history anaphylactic shock , asthma , urticaria allergic reaction previous vaccination know hypersensitivity vaccine component , latex allergy . 5 . Experienced significant acute chronic infection within previous 7 day experience fever ( temperature ≥ 38.0°C [ 100.4°F ] ) within previous 3 day . 6 . Any confirmed suspected immunosuppressive immunodeficient condition , base medical history physical examination . 7 . Received treatment systemic administration corticosteroid ( PO/IV/IM ) 14 consecutive day birth 8 . Ever receive blood , blood product and/or plasma derivative parenteral immunoglobulin preparation ( include Hepatitis B immune globulin ) time since birth full length study . 9 . Any bleed disorder consider contraindication intramuscular injection blood draw . 10 . Any condition , opinion investigator , might interfere result study pose additional risk subject due participation study . 11 . Received plan receive investigational nonregistered medicinal product birth throughout study . 12 . Received oral parenteral antibiotic treatment 3 day prior schedule blood draw ( topical antibiotic acceptable , include antibiotic eye drop ) . 13 . Relatives site research staff work study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>